Azacitidine plus donor cells to prevent AML relapse after transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether adding a chemotherapy drug (azacitidine) along with donor immune cells can help prevent acute myeloid leukemia (AML) from coming back after a stem cell transplant. It is for people who had a half-matched (haploid) transplant and are at high risk for relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You had a half-matched stem cell transplant for AML.
- Your cancer was high-risk before transplant (e.g., not in remission or poor genetics).
- Your blood counts are stable (neutrophils above 1 and platelets above 50).
- You do not have active graft-versus-host disease (GVHD) that is grade II or higher.
- You are able to donate or have donor lymphocytes available.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (a demethylating agent and venetoclax) to help prevent high-risk T-cell lymphoma or leukemia from coming back after a stem cell transplant. It is for patients who have certain risk factors for relapse.
This trial tests a combination of two drugs, azacitidine and venetoclax, for people with acute myeloid leukemia (AML) who have achieved remission after initial chemotherapy but still have tiny amounts of leukemia cells left (measurable residual disease). The goal is to see if this treatment can clear those remaining cells before a stem cell transplant.
This trial tests different chemotherapy induction, consolidation (follow-up treatment), and strategies to prevent complications after an allogeneic stem cell transplant. It aims to improve overall survival and reduce serious transplant side effects like graft-versus-host disease (GVHD).
This trial tests two medicines given after a bone-marrow transplant to help lower the chance of acute myeloid leukemia (AML) coming back. It is aimed at people with higher-risk AML and checks safety along with whether the medicines can help prevent relapse.
This trial tests whether two drugs—ruxolitinib (a JAK inhibitor) and azacitidine (a low-dose chemotherapy)—can help prevent acute myeloid leukemia from coming back after you receive a stem cell transplant from an unrelated donor. The transplant uses a gentler conditioning approach to reduce side effects while fighting the cancer.
This trial tests an oral medication (azacitidine) for people with AML who are in remission and planning a stem cell transplant. It focuses on patients who face health disparities, such as financial or access barriers, to help make transplant more successful for everyone.
Hear when a new Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.